X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA WYETH LTD ALEMBIC PHARMA/
WYETH LTD
 
P/E (TTM) x 26.9 27.7 97.0% View Chart
P/BV x 5.4 5.3 101.4% View Chart
Dividend Yield % 0.6 1.3 49.2%  

Financials

 ALEMBIC PHARMA   WYETH LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
WYETH LTD
Mar-13
ALEMBIC PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs6451,044 61.8%   
Low Rs470818 57.4%   
Sales per share (Unadj.) Rs166.1298.6 55.6%  
Earnings per share (Unadj.) Rs21.957.2 38.3%  
Cash flow per share (Unadj.) Rs27.558.4 47.1%  
Dividends per share (Unadj.) Rs4.0017.00 23.5%  
Dividend yield (eoy) %0.71.8 39.3%  
Book value per share (Unadj.) Rs117.8249.5 47.2%  
Shares outstanding (eoy) m188.5222.72 829.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.1 107.6%   
Avg P/E ratio x25.516.3 156.5%  
P/CF ratio (eoy) x20.315.9 127.2%  
Price / Book Value ratio x4.73.7 126.8%  
Dividend payout %18.329.7 61.5%   
Avg Mkt Cap Rs m105,09021,157 496.7%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m6,228400 1,557.0%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m31,3086,783 461.5%  
Other income Rs m70353 19.9%   
Total revenues Rs m31,3787,136 439.7%   
Gross profit Rs m6,4311,617 397.6%  
Depreciation Rs m1,05527 3,964.7%   
Interest Rs m346 618.2%   
Profit before tax Rs m5,4131,938 279.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-810-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,204632 190.4%   
Profit after tax Rs m4,1281,301 317.4%  
Gross profit margin %20.523.8 86.2%  
Effective tax rate %22.232.6 68.2%   
Net profit margin %13.219.2 68.8%  
BALANCE SHEET DATA
Current assets Rs m18,2476,984 261.3%   
Current liabilities Rs m11,2352,056 546.5%   
Net working cap to sales %22.472.6 30.8%  
Current ratio x1.63.4 47.8%  
Inventory Days Days8699 86.2%  
Debtors Days Days6124 256.3%  
Net fixed assets Rs m20,035244 8,201.1%   
Share capital Rs m377227 165.9%   
"Free" reserves Rs m21,8245,441 401.1%   
Net worth Rs m22,2015,668 391.7%   
Long term debt Rs m5,00025 20,000.0%   
Total assets Rs m39,4117,901 498.8%  
Interest coverage x160.2353.3 45.3%   
Debt to equity ratio x0.20 5,106.0%  
Sales to assets ratio x0.80.9 92.5%   
Return on assets %10.616.5 63.9%  
Return on equity %18.622.9 81.0%  
Return on capital %19.734.0 57.9%  
Exports to sales %46.40.2 21,278.4%   
Imports to sales %10.536.3 28.9%   
Exports (fob) Rs m14,53515 98,208.1%   
Imports (cif) Rs m3,2882,465 133.4%   
Fx inflow Rs m14,72215 96,852.6%   
Fx outflow Rs m7,0262,677 262.4%   
Net fx Rs m7,696-2,662 -289.1%   
CASH FLOW
From Operations Rs m3,124923 338.4%  
From Investments Rs m-8,844317 -2,790.7%  
From Financial Activity Rs m5,026-481 -1,045.0%  
Net Cashflow Rs m-693759 -91.3%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 2.9 11.3 25.7%  
FIIs % 9.1 7.2 126.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 30.4 45.7%  
Shareholders   49,328 21,978 224.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  MERCK LTD  GSK PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 19, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - ALEMBIC LTD COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS